Quantisnow Logo
Dashboard

Amendment: SEC Form SC 13G/A filed by Jaguar Health Inc.

$JAGX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $JAGX alert in real time by email
SC 13G/A 1 jagx.txt 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Jaguar Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 47010C805 (CUSIP Number) John Fife, 303 E Wacker Dr, Suite 1040 Chicago, IL 60601 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 18, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) X Rule 13d-1(c) ? Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).? CUSIP No. 47010C805 13G Page 2 of 9 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Iliad Research & Trading, L.P. 11-3688679 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Utah NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 795,743 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 795,743 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 795,743 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.13*% 12. TYPE OF REPORTING PERSON (see instructions) PN FOOTNOTES *Based on the 8.716,266 shares outstanding on July 17, 2024 ? CUSIP No. 47010C805 13G Page 3 of 9 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Iliad Management, LLC 20-0411071 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 795,743 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 795,743 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 795,743 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.13*% 12. TYPE OF REPORTING PERSON (see instructions) OO FOOTNOTES *Based on the 8.716,266 shares outstanding on July 17, 2024 ? CUSIP No. 47010C805 13G Page 4 of 9 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Fife Trading, Inc. 36-4151891 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Illinois NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 795,743 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 795,743 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 795,743 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.13*% 12. TYPE OF REPORTING PERSON (see instructions) CO FOOTNOTES *Based on the 8.716,266 shares outstanding on July 17, 2024 ? CUSIP No. 47010C805 13G Page 5 of 9 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) John M. Fife 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 795,743 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 795,743 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 795,743 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.13*% 12. TYPE OF REPORTING PERSON (see instructions) IN FOOTNOTES *Based on the 8.716,266 shares outstanding on July 17, 2024 ? CUSIP No. 47010C805 13G Page 6 of 9 Pages Item 1. (a) Name of Issuer Jaguar Health, Inc. (b) Address of Issuer?s Principal Executive Offices 200 Pine Street, Suite 400 San Francisco, CA 94104 Item 2. (a) Name of Person Filing This report is filed by Iliad Research and Trading, LP, Iliad Management, LLC, Fife Trading, Inc., and John M. Fife with respect to the shares of Common Stock, $0.0001 par value per share, of the Issuer that are directly beneficially owned by Iliad Research and Trading, LP and indirectly beneficially owned by the other reporting and filing persons. (b) Address of the Principal Office or, if none, residence 303 East Wacker Drive, Suite 1040, Chicago, IL 60601 (c) Citizenship Iliad Research and Trading, LP is a Utah limited partnership. Iliad Management, LLC is a Delaware limited liability company. Fife Trading, Inc. is an Illinois corporation. John M. Fife is a United States citizen. (d) Title of Class of Securities Common Stock $0.0001 par value per share (e) CUSIP Number 47010C805 Item 3. If this statement is filed pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ? Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) ? Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) ? Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) ? Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) ? An investment adviser in accordance with ?240.13d-1(b)(1)(ii)(E); (f) ? An employee benefit plan or endowment fund in accordance with ?240.13d- 1(b)(1)(ii)(F); (g) ? A parent holding company or control person in accordance with ?240.13d- 1(b)(1)(ii)(G); (h) ? A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ? A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ? Group, in accordance with ?240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 795,743 (b) Percent of class: 9.13% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 795,743 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 795,743 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ? . N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 47010C805 13G Page 9 of 9 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 7/22/2024 Date Iliad Research & Trading, L.P. /s/ John Fife Signature John Fife/President Name/Title Iliad Management, LLC /s/ John Fife Signature John Fife/President Name/Title Fife Trading, Inc. /s/ John Fife Signature John Fife/President Name/Title John M. Fife /s/ John Fife Signature John Fife Name/Title
Get the next $JAGX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$JAGX

DatePrice TargetRatingAnalyst
7/7/2021$5.00Overweight
Cantor Fitzgerald
More analyst ratings

$JAGX
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

    MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

    $AEMD
    $ASPI
    $ATCH
    $BNRG
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

  • Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

    MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com. For updates, follow us on Twitter. Day 1March 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go

    $AEMD
    $ASPI
    $ATCH
    $BNRG
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

  • Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

    MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

$JAGX
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$JAGX
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$JAGX
 SEC Filings

See more

$JAGX
 Leadership Updates

Live Leadership Updates

See more

  • Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

    FDA-approved Gelclair® is company's third commercialized prescription productSusan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals."Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets. We ar

    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

    Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller Collis to the role of Senior Vice President of Growth Strategy."Cathy Collis was instrumental in bringing about the Gelclair in-license agreement. She is a results-oriented commercial leader with more than 25 years of experience in the biopharmaceutical industry, and

    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International

    Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S.Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium priceSAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International. A European pharmaceutical industry leader and entrepreneur with more than 35 years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, Dr

    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$JAGX
 Financials

Live finance-specific insights

See more

  • Jaguar Health Reports 2020 Financial Results and Business Updates

    Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020. 2020 Company Financial Results: Mytesi® Net Product Revenue: 2020 Mytesi net sales were approximately $9.3 million, and Mytesi gross (non-GAAP) sales were approximately $20.4 million, an increase of 64% and 148%, respectively, year over year. In 2020, the Company's animal product research and development efforts were intentionally minimal, and Jaguar's animal-related sales were also minimal.

    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$JAGX
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more